Details for Patent: 8,158,781

Summary for Patent: 8,158,781

Title:	Polymorphic forms α, β and γ of rifaximin
Abstract:	Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Inventor(s):	Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
Assignee:	Alfasigma SpA
Application Number:	US13/041,332
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,158,781
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 8,158,781

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 8,158,781

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Italy	MI2003A2144	Nov 07, 2003

International Family Members for US Patent 8,158,781

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	043547
Argentina	081991
Argentina	081992
Austria	421965
Austria	421966
Austria	E361927